AstraZeneca Scores 77% in Growth Model Evaluation

AstraZeneca PLC receives a strong rating of 77% based on its fundamentals. The stock shows positive characteristics for growth-oriented investors, indicating potential for upward movement in stock prices.

Date: 08-03-2025

AI Rating: 7

AstraZeneca Performance Analysis

AstraZeneca PLC (ADR) has been evaluated using the P/B Growth Investor model and scored 77%. The score reflects favorable underlying fundamentals and a stock valuation that aligns with the growth strategy. This analysis suggests that investors may find it appealing as the stock's growth characteristics are aligned with future sustainability.

The model assesses various criteria for stock evaluation, where the following aspects have shown positive results:

Book/Market Ratio: PASS
Return on Assets: PASS
Cash Flow from Operations to Assets: PASS
Cash Flow from Operations to Assets vs. Return on Assets: PASS
Return on Assets Variance: PASS
Sales Variance: PASS
Capital Expenditures to Assets: PASS

However, there are some areas of concern:

Advertising to Assets: FAIL
Research and Development to Assets: FAIL

Despite the failures in advertising and research and development, AstraZeneca's overall score indicates a healthy position for growth. The failure in R&D might indicate areas for innovation but does not drastically affect the overall rating.

Stocks: AZN